ADC Therapeutics SA

Welcome to the ADC Therapeutics First Quarter 2022 Financial Results Conference Call. My name is Michelle, and I will be the operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star, then 1 on your touchtone phone. I will now turn the call over to Amanda Hamilton, Investor Relations Manager. Amanda, you may begin.

Thank you, operator. This morning, we issued a press release announcing our first quarter 2022 financial results and business update. This release is available on the ADCT website at ir.adctherapeutics.com under the press releases section. On today's call, Chris Martin, former chief executive officer, Jennifer Herron, chief commercial officer, Joe Camardo, chief medical officer, and Jen Creel, chief financial officer, will discuss recent business highlights and review our first quarter 2022 financial results before opening the call for questions. We will also have a brief introduction from our new Chief Executive Officer, Amit Mallet. As a reminder, this conference call may contain forward-looking statements. Such statements are subject to risks and uncertainties. For additional information concerning forward-looking statements and factors that could cause actual results to differ materially from those expressed or implied in these statements, we refer you to the section titled Cautionary Statement Regarding Forward-Looking Statements in Exhibit 99.2 of our report on Form 6-K filed with the U.S. Securities and Exchange Commission earlier today. Such statements speak only as of the date of this conference call, and we expressly disclaim any obligation or undertaking to update these forward-looking statements unless required to do so by applicable law. Today's presentation also includes non-IFRS financial measures. These non-IFRS measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with IFRS. You should research the information contained in the company's first quarter earnings release for definitional information and reconciliations of historical non-IFRS measures to the comparable IFRS financial measures. It is now my pleasure to pass the call over to Chris Martin. Chris?

Thank you, Amanda, and good morning, everyone. Since co-founding ADC Therapeutics in 2011, I've had the privilege of taking our proprietary ADC technology from discovery to the bench to the clinic, then to our first FDA approval of Zinlonza. It is extremely rewarding to see Zinlonza benefiting patients and addressing an unmet need in the third-line plus DLBCL market. I've seen the company grow from a private startup to a New York Stock Exchange listed company. We now have over 300 employees, a commercial product on the market in Zinlanta, Cami progressing to a BLA submission, and five promising solid tumor programs in development. The approval of Zinlanta was a highlight for me, and since then I've been contemplating my next steps. With the company and the pipeline in such a strong position, I'm delighted to hand the CEO role to Amis Malik. I'm extremely confident that he is the right person to lead the company into its next chapter of growth from here. Logistically, I will serve as an advisor to the company for the next three months to ensure a seamless transition, and I'm very happy to be serving as a non-executive member of the Board of Directors and the Chair of the Science and Technology Committee. Amit has significant experience in oncology and commercialization, and a compelling vision for leading ADC Therapeutics in its next phase of growth. Amit spent 16 years at Novartis, where he ultimately served as Executive Vice President and Head of US Oncology, a $6 billion division of Novartis. Prior to that, he held various leadership roles at Novartis Oncology, including Head of Global Marketing, Value and Access, and Head of Latin America and Canada. He also served as Global Head of Biopharmaceuticals and Oncology Injectables at Sanbos and Head of Global Strategic Planning at Novartis Pharmaceuticals. Amit most recently served as CEO of Raphael Holdings, a biotech company focused on developing oncology and immune therapies. ADCT will benefit greatly from Amit's wide range of operational and strategic experiences, as well as his oncology expertise. I would like to formally welcome Amit to the ADCT and invite him to say a few words. Amit.